Loading
GB
Global Blood Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Fink Eric, was filed 10 May 2021.
Global Blood Therapeutics, Inc.: what insiders have been doing
Global Blood Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Global Blood Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 6 October 2022.
The full history, which starts in 2016, counts 14 purchases against 4 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
106
Thresholds
n/a
Buy Volume
€15,633
14 ops. · all time
Sell Volume
€516,083
4 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$167.7M
Net income-US$261M-155.6% margin
Last declaration on 6 October 2022
Declarations106 total
6,716 sharesCommon StockSEC:0000899243-22-033146:0
5,980 sharesCommon StockSEC:0000899243-22-033151:0
26,739 sharesCommon StockSEC:0000899243-22-033145:0
37,865 sharesCommon StockSEC:0000899243-22-033162:0
39,680 sharesCommon StockSEC:0000899243-22-033147:0
22,000 shares0Common StockSEC:0000899243-22-033150:0
3,308 sharesCommon StockSEC:0000899243-22-033160:0
9,112 sharesCommon StockSEC:0000899243-22-033158:0
576,318 sharesCommon StockSEC:0000899243-22-033149:0
11,437 sharesCommon StockSEC:0000899243-22-033159:0
9,037 sharesCommon StockSEC:0000899243-22-033161:0
5,376 sharesCommon StockSEC:0000899243-22-033157:0
43,077 sharesCommon StockSEC:0000899243-22-033144:0
26,437 sharesCommon StockSEC:0000899243-22-033156:0
6,637 sharesCommon StockSEC:0000899243-22-033163:0
3,500 shares0Common StockSEC:0000899243-22-032687:0
23,597 shares@ US$12.9549.7% of flowCommon StockSEC:0000899243-22-032264:0
23,653 shares@ US$16.40100.0% of flowCommon StockSEC:0000899243-22-032265:0
221,200 shares0Common StockSEC:0000899243-22-032261:0
414 shares@ US$25.371.6% of flowCommon StockSEC:0000899243-22-030480:0
365 shares@ US$25.3730.9% of flowCommon StockSEC:0000899243-22-030479:0
385 shares@ US$25.3746.6% of flowCommon StockSEC:0000899243-22-030473:0
25 of 106 declarations
About Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) was a United States biopharmaceutical company historically listed on the NASDAQ under the ticker GBT, before being acquired by Pfizer. For investors tracking SEC Form 4 insider activity or legacy filings, the key point is that GBT is no longer an independent publicly traded company; its business and assets were folded into Pfizer following the announced transaction in 2022. The company’s headquarters were in South San Francisco, California, placing it in one of the most important U.S. biotech clusters. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai))
Founded in 2011, GBT was built as a focused rare-disease biopharma company dedicated to discovering, developing, and delivering therapies for sickle cell disease. Its strategy was highly specialized: rather than pursuing a broad pipeline across multiple therapeutic areas, the company concentrated capital and scientific resources on hemoglobin S biology and the mechanisms that drive red blood cell sickling. That narrow focus gave GBT a clear identity in the market and made it a recognizable name in rare hematology. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai))
Read moreShow less
GBT’s flagship commercial product was Oxbryta (voxelotor), which the company described as the first FDA-approved medicine that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in sickle cell disease. The company also advanced pipeline assets including inclacumab, a P-selectin inhibitor in Phase 3 development aimed at reducing vaso-occlusive crises, and GBT601, a next-generation hemoglobin S polymerization inhibitor. These programs positioned GBT as both a commercial-stage and development-stage rare-disease company. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai))
From a competitive standpoint, GBT operated in a specialized and medically underserved market. Sickle cell disease represents a high-unmet-need therapeutic area, which historically supported premium valuation for companies able to bring differentiated science to market. At the same time, the investment case carried the usual biotech risks: regulatory uncertainty, clinical trial execution, reimbursement challenges, and concentration risk around a small number of lead assets. GBT’s eventual takeover by Pfizer underscored the strategic value of its hematology franchise and the interest of large-cap pharma in rare blood disorders. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai))
A major recent event was Pfizer’s completion of the acquisition, which ended GBT’s life as a standalone public company. For market context, the company was a U.S.-based NASDAQ-listed biotech, but any current investor analysis should treat it as a historical reference point rather than an active listed security. The legacy of GBT remains its scientific and commercial contribution to sickle cell disease treatment development. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-global-blood-therapeutics?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
